Načítá se...
Ceftolozane/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy
The current prevalence of infections caused by multidrug-resistant (MDR) organisms is a global threat, and thus, the development of new antimicrobial agents with activity against these pathogens is a healthcare priority. Ceftolozane–tazobactam (C/T) is a new combination of a cephalosporin with a β-l...
Uloženo v:
| Vydáno v: | Infect Drug Resist |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6613001/ https://ncbi.nlm.nih.gov/pubmed/31308706 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IDR.S180905 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|